Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 31.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 340,495 shares of the company's stock after selling 156,961 shares during the period. Assenagon Asset Management S.A. owned approximately 0.55% of Fulcrum Therapeutics worth $1,216,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of FULC. Jane Street Group LLC increased its position in shares of Fulcrum Therapeutics by 54.3% during the first quarter. Jane Street Group LLC now owns 535,062 shares of the company's stock valued at $5,051,000 after acquiring an additional 188,212 shares during the last quarter. Vanguard Group Inc. raised its position in Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company's stock valued at $23,965,000 after purchasing an additional 18,681 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics during the first quarter worth $308,000. Dimensional Fund Advisors LP boosted its position in shares of Fulcrum Therapeutics by 13.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company's stock worth $9,182,000 after buying an additional 176,114 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Fulcrum Therapeutics by 47.7% during the second quarter. Marshall Wace LLP now owns 333,161 shares of the company's stock worth $2,066,000 after buying an additional 107,588 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC traded up $0.05 on Friday, reaching $3.21. The stock had a trading volume of 420,759 shares, compared to its average volume of 992,557. The stock has a market cap of $200.31 million, a P/E ratio of -9.17 and a beta of 2.21. Fulcrum Therapeutics, Inc. has a 12-month low of $2.87 and a 12-month high of $13.70. The business's 50-day moving average price is $4.81 and its 200 day moving average price is $6.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.93. The business had revenue of $80.00 million during the quarter, compared to analysts' expectations of $80.00 million. During the same quarter last year, the company earned ($0.38) EPS. On average, sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Bank of America lowered Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Royal Bank of Canada cut shares of Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price target for the stock from $15.00 to $4.00 in a research report on Thursday, September 12th. Leerink Partners restated a "market perform" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. HC Wainwright lowered shares of Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $17.00 to $4.00 in a report on Friday, September 13th. Finally, Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Fulcrum Therapeutics presently has an average rating of "Hold" and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.